Shares of Alcobra Ltd. (NASDAQ:ADHD) traded up 4.6% during trading on Tuesday . The stock traded as high as $5.17 and last traded at $4.97, with a volume of 91,253 shares trading hands. The stock had previously closed at $4.75.

Several analysts have recently commented on the company. Barclays PLC assumed coverage on Alcobra in a report on Monday, August 1st. They issued an “equal weight” rating and a $8.00 price target for the company. Zacks Investment Research raised Alcobra from a “sell” rating to a “hold” rating in a report on Tuesday, July 26th. Roth Capital reissued a “buy” rating and issued a $12.00 price target on shares of Alcobra in a report on Tuesday, June 21st. Canaccord Genuity assumed coverage on Alcobra in a report on Tuesday, June 7th. They issued a “buy” rating for the company. Finally, Cantor Fitzgerald assumed coverage on Alcobra in a report on Tuesday, June 7th. They issued a “buy” rating and a $16.00 price target for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $11.13.

The stock has a 50-day moving average of $4.45 and a 200 day moving average of $4.56. The stock’s market capitalization is $135.33 million.

Alcobra (NASDAQ:ADHD) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. Equities analysts predict that Alcobra Ltd. will post ($0.97) EPS for the current year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.